Table 1.
Distribution of patients undergoing ASCT at our institute
| Type of primary disease | LN | MN | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PCN | HL | NHL | ALL | AML | CML-CP/ AP | |||||||||||||
| MM | PCL | LCDD | DLBCL | ALCL | PTCL- NOS | Pre-B | ||||||||||||
| Total patients (n=65) | 46 | 1 | 1 | 7 | 1 | 1 | 2 | 1 | 3 | 2 | ||||||||
| Median age (range) (yrs) | 51 (24-65) | 50 | 49 | 23 (14-35) | 36 | 12 | 39 (30-48) | 11 | 41 (14-54) | 22 (7-37) | ||||||||
| Sex (M:F) | 2.3:1 | M | M | 1.33:1 | M | F | 1:1 | F | 1:2 | 1:1 | ||||||||
| Time of diagnosis (mth-yr) | 2008-2019 | 11-2011 | 11-2019 | 2001-2018 | 03-2015 | 09-2017 | 2019 | 06-2012 | 2011-2017 | 2003-2004 | ||||||||
| Treatment received pre-ASCT | Thal-Dex/ VCD/ VTD/CTD | VTD | VTD | ABVD/ OPPA-COPP/ GDP/Mini BEAM | R-CHOP/ R-DA EPOCH/ R-GDP | CHOEP/ GDP | CHOP | BFM 90 | (3+7)/ HIDAC | Imatinib | ||||||||
| Remission status | sCR | CR | VGPR | PR | SD | sCR | VGPR | CMR | PD | CMR | CMR | CMR | CR2 | CR1 | CR2 | Complete molecular response | ||
| 10 | 17 | 16 | 2 | 1 | 6 | 1 | 2 | 1 | ||||||||||
| Median time to ASCT (range) (mth) | 10 (2-144) | 13 (6-42) | 10 (2-41) | 19 (18-20) | 23 | 7 | 10 | 88 (19-189) | 34 | 21 | 10 | 3.5 | 17.5 (16-19) | 81 | 87 (80-94) | |||
| Conditioning regimen | Mel 140-200mg/m2 | BEAM | BEAM | Flu-Mel | Flu-Mel/ Bu-Cy | Flu-Mel | Bu-Cy | |||||||||||
| Type of product infusion | Fresh product | Cryopreserved product | ||||||||||||||||
| Median pre-harvest CD34+ (range) (cells/µL) | 32 (3.16-79.22) | ND | 9 | 10.19 (8.79-11.61) | 10 | ND | 7.36 | ND | ND | 28.21 | ND | |||||||
| Median post-harvest CD34+ (range) (×106/kg) | 5.3 (1.6-9.34) | 4.5 | 6 | 4.8 (4.2-8.04) | 3.01 | 3.1 | 6.15 (5.26-7.04) | 5.78 | 4.5 (3.83-5.17) | 8.2 (5.94-10.55) | ||||||||
| Median time to engraftment (neutrophil) (Range) (dys) | 11 (9-17) | 10 | 12 | 11 (8-17) | 13 | 14 | 15 (11-19) | 18 | 15 (13-17) | 10.5 (10-11) | ||||||||
| Median time to engraftment (platelet) (Range) (dys) | 11 (9-15)
[1 patient did not engraft] |
26 | 15 | 12 (10-33) | 13 | 15 | 16 (11-21) | 12 | 14 (10-18) | 12.5 (12-13) | ||||||||
| Median time to FN (range) (dys) | 4 (-2 to 12) | - | 3 | 2 (-7 to 10) | 5 | 5 | 2.5 (2-3) | 6 | 6 (5-7) | 0 | ||||||||
| Other complications (Relapse) | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | ||||||||
| Alive (as on Aug 2020) | 32 | 0 | 1 | 7 | 1 | 1 | 1 | 0 | 1 | 2 | ||||||||
| Status not known (as on Aug 2020) | 9 | - | - | - | - | - | 1 | - | 1 | - | ||||||||
The data for pre-harvest CD34+ concentration was available in 26 patients.
LN, lymphoid neoplasm; MN, myeloid neoplasm; PCN, plasma cell neoplasm; MM, multiple myeloma; PCL, plasma cell leukemia; LCDD, light chain deposition disease; HL, hodgkins lymphoma; NHL, non hodgkins lymphoma; PTCL-NOS, peripheral T-cell lymphoma-not otherwise specified; ALCL, anaplastic large cell lymphoma; DLBCL, diffuse large B-cell lymphoma; ALL, acute lymphoblastic leukemia; Pre-B, Pre B ALL; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; CP, chronic phase; AP, accelerated phase; Thal-Dex, thalidomide-dexamethasone; VCD, bortezomib cyclophosphamide dexamethasone; VTD, bortezomib thalidomide dexamethasone; CTD, cyclophosphamide thalidomide dexamethasone; Mel, melphalan; ABVD, doxorubicin bleomycin vinblastine dacarbazine; OPPA-COPP, vincristine procarbazine prednisone doxorubicin (OPPA) - cyclophosphamide vincristine procarbazine prednisone (COPP); GDP, gemcitabine dexamethasone cisplatin; BEAM, BCNU etoposide cytarabine melphalan; CHOP, cyclophosphamide doxorubicin vincristine prednisone; CHOEP, CHOP+etoposide; R-CHOP, rituximab-CHOP; R-DA EPOCH, dose adjusted R-CHOP+etoposide; BFM90, berlin frankfurt muenster 90 protocol; Flu-Mel, fludarabine-melphalan; (3+7), daunorubicin+cytarabine; HIDAC, high dose cytarabine; Bu-Cy, busulphan-cytarabine; CR, complete response; sCR, stringent CR; VGPR, very good partial response; PR, partial response; SD, stable disease; CMR, complete metabolic response; PD, progressive disease; CR 1/2, complete remission 1/2; dys, days; mth, months; yrs, years; M, male; F, female; ASCT, autologous stem cell transplant; FN, febrile neutropenia; OS, overall survival; ND, not done.